Bambusa Therapeutics, a portfolio company of INCE Capital, was invited to present at the 44th Annual J.P. Morgan Healthcare Conference on January 13.
Bambusa Therapeutics is a clinical-stage biotechnology company advancing next-generation bispecific antibodies for immunology and inflammation. Dr. Shanshan Xu, Founder and CEO, presented on behalf of Bambusa at the JPM healthcare event.
During the presentation, Bambusa highlighted the company’s continued momentum across its differentiated immunology and inflammation pipeline, including progress across multiple clinical and preclinical programs built on its next-generation bispecific antibody platform. The session underscored Bambusa’s execution-first culture, rapidly expanding clinical footprint, and growing visibility among global investors and strategic partners.
With multiple clinical programs advancing in parallel, Bambusa is entering 2026 positioned to deliver up to 10 clinical readouts, including five proof-of-concept studies, as Bambusa continues to advance new possibilities for patients with type 2 inflammatory diseases.
In early January, Bambusa announced dosing of the first patient in the Phase Ib clinical trial of BBT002, a novel platform-in-a-molecule bispecific antibody targeting IL-4Rα and IL-5, in patients with chronic obstructive pulmonary disease (COPD). The Phase Ib study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BBT002 in COPD as well as other type 2 inflammatory respiratory indications, including asthma and chronic rhinosinusitis with nasal polyps. Initial data are anticipated in the second half of 2026.
Type 2 inflammation underlies a continuum of allergic and inflammatory disorders that evolve across the human lifespan — representations range from atopic dermatitis and food allergy in early childhood, to asthma and chronic rhinosinusitis with nasal polyps in adulthood, and ultimately to COPD in later life. Despite this shared biology, current therapies largely address individual disease manifestations in isolation, often leaving patients with incomplete or transient control as their disease evolves.
BBT002 is designed to simultaneously inhibit IL-4/IL-13 and IL-5 signaling, two central and complementary drivers of type 2 inflammation that together shape disease expression across multiple organ systems and stages of life. By targeting both pathways in a single, long-acting molecule, BBT002 has the potential to deliver broader and more durable suppression of underlying disease biology than existing single-target therapies, offering a unified therapeutic approach across respiratory and other type 2 inflammatory conditions.
In Bambusa’s blueprint, by 2028, BBT001 and BBT002 are expected to be advancing through pivotal studies in large indications, while in parallel BBT003 and BBT004 are delivering proof-of-concept data.
